{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:04:27Z","timestamp":1773259467500,"version":"3.50.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12032-022-01699-8","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:03:01Z","timestamp":1652659381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Alterations in cellular metabolisms after Imatinib therapy: a review"],"prefix":"10.1007","volume":"39","author":[{"given":"Veerandra","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonu Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Villayat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Jyotirmayee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-6086","authenticated-orcid":false,"given":"Malkhey","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"1699_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0729-2","author":"S Soverini","year":"2019","unstructured":"Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019. https:\/\/doi.org\/10.1186\/s13045-019-0729-2.","journal-title":"J Hematol Oncol"},{"key":"1699_CR2","volume-title":"Adverse events and oncotargeted kinase inhibitors","author":"G Tridente","year":"2017","unstructured":"Tridente G. Adverse events. In: Adverse events and oncotargeted kinase inhibitors. Amsterdam: Elsevier; 2017."},{"issue":"1","key":"1699_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-021-01462-5","volume":"38","author":"P Singh","year":"2021","unstructured":"Singh P, Kumar V, Gupta SK, Kumari G, Verma M. Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: a review. Med Oncol. 2021;38(1):1\u201316. https:\/\/doi.org\/10.1007\/s12032-021-01462-5.","journal-title":"Med Oncol"},{"issue":"4","key":"1699_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.21276\/apjhs.2018.5.4.12","volume":"5","author":"P Singh","year":"2018","unstructured":"Singh P, Gupta SK, Ali V, Verma M. Downregulation of Bcr-Abl oncogene in chronic myeloid leukemia by micro RNAs. Asian Pac J Health Sci. 2018;5(4):65\u201384. https:\/\/doi.org\/10.21276\/apjhs.2018.5.4.12.","journal-title":"Asian Pac J Health Sci"},{"issue":"1","key":"1699_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):1\u201314. https:\/\/doi.org\/10.1186\/s13045-018-0624-2.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1699_CR6","first-page":"139","volume":"295","author":"E Buchdunge","year":"2000","unstructured":"Buchdunge E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1):139\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"1699_CR7","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/S0959-8049(02)80603-7","volume":"38","author":"GD Demetri","year":"2002","unstructured":"Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002;38:S52\u20139. https:\/\/doi.org\/10.1016\/S0959-8049(02)80603-7.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1699_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.leukres.2003.10.003","volume":"28","author":"GW Krystal","year":"2004","unstructured":"Krystal GW. Imatinib mesylate (STI571) for myeloid malignancies other than CML. Leuk Res. 2004;28(1):53\u20139. https:\/\/doi.org\/10.1016\/j.leukres.2003.10.003.","journal-title":"Leuk Res"},{"issue":"12","key":"1699_CR9","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1634\/theoncologist.12-12-1390","volume":"12","author":"CE de Kogel","year":"2007","unstructured":"de Kogel CE, Schellens JHM. Imatinib. Oncologist. 2007;12(12):1390\u20134. https:\/\/doi.org\/10.1634\/theoncologist.12-12-1390.","journal-title":"Oncologist"},{"key":"1699_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01689.x","author":"S Vaidya","year":"2011","unstructured":"Vaidya S, Ghosh K, Vundinti BR. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol. 2011. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01689.x.","journal-title":"Eur J Haematol"},{"key":"1699_CR11","first-page":"49","volume-title":"Imatinib: the first-line CML therapy","author":"C Fava","year":"2021","unstructured":"Fava C, Rege-Cambrin G, Saglio G. Imatinib: the first-line CML therapy. Cham: Springer; 2021. p. 49\u201359."},{"issue":"1","key":"1699_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","volume":"2013","author":"T Hughes","year":"2013","unstructured":"Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology. 2013;2013(1):168\u201375. https:\/\/doi.org\/10.1182\/asheducation-2013.1.168.","journal-title":"Hematology"},{"issue":"7","key":"1699_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/17474086.2017.1339599","volume":"10","author":"AE Eskazan","year":"2017","unstructured":"Eskazan AE, Ozmen D. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events\u2014is better always good? Expert Rev Hematol. 2017;10(7):583\u20136. https:\/\/doi.org\/10.1080\/17474086.2017.1339599.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"1699_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006.","journal-title":"Cancer Cell"},{"key":"1699_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-022-04376-6","author":"V Kumar","year":"2022","unstructured":"Kumar V, Singh P, Gupta SK, Ali V, Verma M. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem. 2022. https:\/\/doi.org\/10.1007\/s11010-022-04376-6.","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"1699_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00129785-200505050-00002","volume":"5","author":"N Serkova","year":"2005","unstructured":"Serkova N, Boros LG. Detection of resistance to imatinib by metabolic profiling. Am J Pharmacogenomics. 2005;5(5):293\u2013302. https:\/\/doi.org\/10.2165\/00129785-200505050-00002.","journal-title":"Am J Pharmacogenomics"},{"issue":"3","key":"1699_CR17","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1038\/cddis.2013.60","volume":"4","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4(3):e532\u2013e532. https:\/\/doi.org\/10.1038\/cddis.2013.60.","journal-title":"Cell Death Dis"},{"issue":"3215","key":"1699_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.124.3215.267","volume":"124","author":"S Weinhouse","year":"1956","unstructured":"Weinhouse S, Warburg O, Burk D, Schade AL. On respiratory impairment in cancer cells. Science. 1956;124(3215):269\u201370. https:\/\/doi.org\/10.1126\/science.124.3215.267.","journal-title":"Science"},{"issue":"1","key":"1699_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","volume":"7","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11\u201320. https:\/\/doi.org\/10.1016\/j.cmet.2007.10.002.","journal-title":"Cell Metab"},{"issue":"9","key":"1699_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1101\/gad.1529107","volume":"21","author":"JJ Lum","year":"2007","unstructured":"Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, et al. The transcription factor HIF-1 plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007;21(9):1037\u201349. https:\/\/doi.org\/10.1101\/gad.1529107.","journal-title":"Genes Dev"},{"issue":"4","key":"1699_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/01.mco.0000232894.28674.30","volume":"9","author":"JV Swinnen","year":"2006","unstructured":"Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9(4):358\u201365. https:\/\/doi.org\/10.1097\/01.mco.0000232894.28674.30.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"1","key":"1699_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21\u201335. https:\/\/doi.org\/10.1038\/nrm3025.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"1699_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","volume":"8","author":"T Porstmann","year":"2008","unstructured":"Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8(3):224\u201336. https:\/\/doi.org\/10.1016\/j.cmet.2008.07.007.","journal-title":"Cell Metab"},{"issue":"3","key":"1699_CR24","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/emm.2015.122","volume":"48","author":"H-S Han","year":"2016","unstructured":"Han H-S, Kang G, Kim JS, Choi BH, Koo S-H. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med. 2016;48(3):e218\u2013e218. https:\/\/doi.org\/10.1038\/emm.2015.122.","journal-title":"Exp Mol Med"},{"issue":"2","key":"1699_CR25","doi-asserted-by":"publisher","first-page":"e13360","DOI":"10.1111\/apha.13360","volume":"228","author":"M Tozzi","year":"2020","unstructured":"Tozzi M, Hansen JB, Novak I. Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration. Acta Physiol. 2020;228(2):e13360. https:\/\/doi.org\/10.1111\/apha.13360.","journal-title":"Acta Physiol"},{"key":"1699_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2019.08.001","volume":"28","author":"N Jaiswal","year":"2019","unstructured":"Jaiswal N, Gavin MG, Quinn WJ, Luongo TS, Gelfer RG, Baur JA, et al. The role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis. Mol Metab. 2019;28:1\u201313. https:\/\/doi.org\/10.1016\/j.molmet.2019.08.001.","journal-title":"Mol Metab"},{"issue":"10","key":"1699_CR27","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","volume":"15","author":"DJ Kominsky","year":"2009","unstructured":"Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL\u2013positive cells. Clin Cancer Res. 2009;15(10):3442\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3291.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1699_CR28","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/sj.onc.1208461","volume":"24","author":"K Barnes","year":"2005","unstructured":"Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene. 2005;24(20):3257\u201367. https:\/\/doi.org\/10.1038\/sj.onc.1208461.","journal-title":"Oncogene"},{"issue":"9","key":"1699_CR29","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.3109\/10428194.2016.1142086","volume":"57","author":"BW Ko","year":"2016","unstructured":"Ko BW, Han J, Heo JY, Jang Y, Kim SJ, Kim J, et al. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production. Leuk Lymphoma. 2016;57(9):2180\u20138. https:\/\/doi.org\/10.3109\/10428194.2016.1142086.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1699_CR30","first-page":"389","volume":"48","author":"T-Y Yan","year":"2017","unstructured":"Yan T-Y, Naren D-L, Gong Y-P. The roles of Glut5 in imatinib resistance in the Ph+ acute lymphoblastic leukemia cell. J Sichuan Univ Med Sci Ed. 2017;48(3):389\u201393.","journal-title":"J Sichuan Univ Med Sci Ed"},{"issue":"19","key":"1699_CR31","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","volume":"10","author":"S Gottschalk","year":"2004","unstructured":"Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res. 2004;10(19):6661\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0039.","journal-title":"Clin Cancer Res"},{"issue":"41","key":"1699_CR32","doi-asserted-by":"publisher","first-page":"37747","DOI":"10.1074\/jbc.M105796200","volume":"276","author":"J Boren","year":"2001","unstructured":"Boren J, Cascante M, Marin S, Com\u0131\u0301n-Anduix B, Centelles JJ, Lim S, et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem. 2001;276(41):37747\u201353. https:\/\/doi.org\/10.1074\/jbc.M105796200.","journal-title":"J Biol Chem"},{"issue":"12","key":"1699_CR33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cellbi.2006.08.006","volume":"30","author":"R Hagerkvist","year":"2006","unstructured":"Hagerkvist R, Makeeva N, Elliman S, Welsh N. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol Int. 2006;30(12):1013\u20137. https:\/\/doi.org\/10.1016\/j.cellbi.2006.08.006.","journal-title":"Cell Biol Int"},{"issue":"38","key":"1699_CR34","doi-asserted-by":"publisher","first-page":"13622","DOI":"10.1073\/pnas.0501758102","volume":"102","author":"AM Wolf","year":"2005","unstructured":"Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, et al. The kinase inhibitor imatinib mesylate inhibits TNF-\u03b1 production in vitro and prevents TNF-dependent acute hepatic inflammation. PNAS. 2005;102(38):13622\u20137. https:\/\/doi.org\/10.1073\/pnas.0501758102.","journal-title":"PNAS"},{"issue":"48","key":"1699_CR35","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1073\/pnas.0810246105","volume":"105","author":"C Louvet","year":"2008","unstructured":"Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. PNAS. 2008;105(48):18895\u2013900. https:\/\/doi.org\/10.1073\/pnas.0810246105.","journal-title":"PNAS"},{"issue":"2","key":"1699_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2337\/db08-0080","volume":"58","author":"MS Han","year":"2009","unstructured":"Han MS, Chung KW, Cheon HG, Rhee SD, Yoon C-H, Lee M-K, et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db\/db mice. Diabetes. 2009;58(2):329\u201336. https:\/\/doi.org\/10.2337\/db08-0080.","journal-title":"Diabetes"},{"issue":"2","key":"1699_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.2009.976","volume":"302","author":"S Li","year":"2009","unstructured":"Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes. JAMA. 2009;302(2):179\u2013218. https:\/\/doi.org\/10.1001\/jama.2009.976.","journal-title":"JAMA"},{"issue":"8","key":"1699_CR38","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1210\/jc.2010-0086","volume":"95","author":"S Fitter","year":"2010","unstructured":"Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino ACW. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab. 2010;95(8):3763\u20137. https:\/\/doi.org\/10.1210\/jc.2010-0086.","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"1699_CR39","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood.V124.21.1813.1813","volume":"124","author":"R Zdenek","year":"2014","unstructured":"Zdenek R, Belohlavkova P, Cetkovsky P, Faber E, Klamova H, Ludmila M, et al. Comparison of glucose and lipid metabolism abnormality during nilotinib, imatinib and dasatinib therapy\u2014results of enigma 2 study. Blood. 2014;124(21):1813. https:\/\/doi.org\/10.1182\/blood.V124.21.1813.1813.","journal-title":"Blood"},{"issue":"1","key":"1699_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cmet.2006.06.003","volume":"4","author":"SE Hosch","year":"2006","unstructured":"Hosch SE, Olefsky JM, Kim JJ. Applied mechanics: uncovering how adiponectin modulates insulin action. Cell Metab. 2006;4(1):5\u20136. https:\/\/doi.org\/10.1016\/j.cmet.2006.06.003.","journal-title":"Cell Metab"},{"issue":"3","key":"1699_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/JME-12-0003","volume":"48","author":"S Fitter","year":"2012","unstructured":"Fitter S, Vandyke K, Gronthos S, Zannettino ACW. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. J Mol Endocrinol. 2012;48(3):229\u201340. https:\/\/doi.org\/10.1530\/JME-12-0003.","journal-title":"J Mol Endocrinol"},{"issue":"44","key":"1699_CR42","doi-asserted-by":"publisher","first-page":"33623","DOI":"10.1074\/jbc.M109.085084","volume":"285","author":"N Wijesekara","year":"2010","unstructured":"Wijesekara N, Krishnamurthy M, Bhattacharjee A, Suhail A, Sweeney G, Wheeler MB. Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem. 2010;285(44):33623\u201331. https:\/\/doi.org\/10.1074\/jbc.M109.085084.","journal-title":"J Biol Chem"},{"key":"1699_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-ento-112408-085356","volume":"55","author":"EL Arrese","year":"2010","unstructured":"Arrese EL, Soulages JL. Insect fat body: energy, metabolism, and regulation. Annu Rev Entomol. 2010;55:207\u201325. https:\/\/doi.org\/10.1146\/annurev-ento-112408-085356.","journal-title":"Annu Rev Entomol"},{"key":"1699_CR44","volume-title":"Lehninger principles of biochemistry","author":"AL Lehninger","year":"2005","unstructured":"Lehninger AL, Nelson DL, Cox MM, Cox MM. Lehninger principles of biochemistry. New York: Macmillan; 2005."},{"key":"1699_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/5415767","volume":"2016","author":"Y Jo","year":"2016","unstructured":"Jo Y, Okazaki H, Moon Y-A, Zhao T. Regulation of lipid metabolism and beyond. Int J Endocrinol. 2016;2016:1. https:\/\/doi.org\/10.1155\/2016\/5415767.","journal-title":"Int J Endocrinol"},{"key":"1699_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/978-90-481-8622-8","volume-title":"Cholesterol binding and cholesterol transport proteins","author":"JR Harris","year":"2010","unstructured":"Harris JR. Cholesterol binding and cholesterol transport proteins. Dordrecht: Springer; 2010."},{"key":"1699_CR47","volume-title":"Introduction to lipids and lipoproteins","author":"KR Feingold","year":"2000","unstructured":"Feingold KR, Grunfeld C. Introduction to lipids and lipoproteins. South Dartmouth: MDText.com inc; 2000."},{"issue":"10","key":"1699_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763\u201377. https:\/\/doi.org\/10.1038\/nrc2222.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1699_CR49","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","volume":"24","author":"M Lassila","year":"2004","unstructured":"Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(5):935\u201342. https:\/\/doi.org\/10.1161\/01.ATV.0000124105.39900.db.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"32","key":"1699_CR50","doi-asserted-by":"publisher","first-page":"33944","DOI":"10.18632\/oncotarget.5580","volume":"6","author":"A Iurlo","year":"2015","unstructured":"Iurlo A, Orsi E, Cattaneo D, Resi V, Bucelli C, Orofino N, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015;6(32):33944. https:\/\/doi.org\/10.18632\/oncotarget.5580.","journal-title":"Oncotarget"},{"issue":"9","key":"1699_CR51","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.leukres.2009.02.024","volume":"33","author":"R Gologan","year":"2009","unstructured":"Gologan R, Constantinescu G, Georgescu D, Ostroveanu D, Vasilache D, Dobrea C, et al. Hypolipemiant besides antileukemic effect of imatinib mesylate. Leuk Res. 2009;33(9):1285\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2009.02.024.","journal-title":"Leuk Res"},{"issue":"2","key":"1699_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3324\/haematol.11680","volume":"93","author":"A Franceschino","year":"2008","unstructured":"Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica. 2008;93(2):317\u20138. https:\/\/doi.org\/10.3324\/haematol.11680.","journal-title":"Haematologica"},{"issue":"25","key":"1699_CR53","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1056\/NEJMc052500","volume":"353","author":"M Gottardi","year":"2005","unstructured":"Gottardi M, Manzato E, Gherlinzoni F. Imatinib and hyperlipidemia. N Engl J Med. 2005;353(25):2722\u20133. https:\/\/doi.org\/10.1056\/NEJMc052500.","journal-title":"N Engl J Med"},{"issue":"10","key":"1699_CR54","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1609324.","journal-title":"N Engl J Med"},{"issue":"5","key":"1699_CR55","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1080\/10428194.2016.1228928","volume":"58","author":"M Ellis","year":"2017","unstructured":"Ellis M, Krashin E, Hamburger-Avnery O, Gan S, Elis A, Ashur-Fabian O. The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription. Leuk Lymphoma. 2017;58(5):1172\u20137. https:\/\/doi.org\/10.1080\/10428194.2016.1228928.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1699_CR56","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/sj.bjc.6604946","volume":"100","author":"J Klawitter","year":"2009","unstructured":"Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, Eckhardt SG, et al. Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br J Cancer. 2009;100(6):923\u201331. https:\/\/doi.org\/10.1038\/sj.bjc.6604946.","journal-title":"Br J Cancer"},{"issue":"2","key":"1699_CR57","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","volume":"73","author":"Z Li","year":"2016","unstructured":"Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377\u201392. https:\/\/doi.org\/10.1007\/s00018-015-2070-4.","journal-title":"Cell Mol Life Sci"},{"key":"1699_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.603837","author":"Z Wei","year":"2021","unstructured":"Wei Z, Liu X, Cheng C, Yu W, Yi P. Metabolism of amino acids in cancer. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2020.603837.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1699_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s12276-020-0375-3","volume":"52","author":"EL Lieu","year":"2020","unstructured":"Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med. 2020;52(1):15\u201330. https:\/\/doi.org\/10.1038\/s12276-020-0375-3.","journal-title":"Exp Mol Med"},{"issue":"4","key":"1699_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.tibs.2014.02.004","volume":"39","author":"I Amelio","year":"2014","unstructured":"Amelio I, Cutruzzol\u00e1 F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191\u20138. https:\/\/doi.org\/10.1016\/j.tibs.2014.02.004.","journal-title":"Trends Biochem Sci"},{"issue":"24","key":"1699_CR61","doi-asserted-by":"publisher","first-page":"19786","DOI":"10.1074\/jbc.R112.357194","volume":"287","author":"SC Kalhan","year":"2012","unstructured":"Kalhan SC, Hanson RW. Resurgence of serine: an often neglected but indispensable amino acid. J Biol Chem. 2012;287(24):19786\u201391. https:\/\/doi.org\/10.1074\/jbc.R112.357194.","journal-title":"J Biol Chem"},{"issue":"1","key":"1699_CR62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/bjc.2013.293","volume":"109","author":"B Zhang","year":"2013","unstructured":"Zhang B, Dong L-W, Tan Y-X, Zhang J, Pan Y-F, Yang C, et al. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer. 2013;109(1):14\u201323. https:\/\/doi.org\/10.1038\/bjc.2013.293.","journal-title":"Br J Cancer"},{"issue":"7","key":"1699_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.trecan.2016.06.002","volume":"2","author":"A Nagarajan","year":"2016","unstructured":"Nagarajan A, Malvi P, Wajapeyee N. Oncogene-directed alterations in cancer cell metabolism. Trends Cancer. 2016;2(7):365\u201377. https:\/\/doi.org\/10.1016\/j.trecan.2016.06.002.","journal-title":"Trends Cancer"},{"issue":"4","key":"1699_CR64","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/cncr.20057","volume":"100","author":"BJ Dillon","year":"2004","unstructured":"Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers. Cancer. 2004;100(4):826\u201333. https:\/\/doi.org\/10.1002\/cncr.20057.","journal-title":"Cancer"},{"issue":"7","key":"1699_CR65","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/0008-5472.CAN-06-2519","volume":"67","author":"H Cui","year":"2007","unstructured":"Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M, et al. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res. 2007;67(7):3345\u201355. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2519.","journal-title":"Cancer Res"},{"issue":"10","key":"1699_CR66","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1158\/1535-7163.MCT-08-0589","volume":"7","author":"PL Lorenzi","year":"2008","unstructured":"Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, et al. Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008;7(10):3123\u20138. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0589.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"1699_CR67","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/cgt.2016.28","volume":"23","author":"Y Xu","year":"2016","unstructured":"Xu Y, Lv F, Zhu X, Wu Y, Shen X. Loss of asparagine synthetase suppresses the growth of human lung cancer cells by arresting cell cycle at G0\/G1 phase. Cancer Gene Ther. 2016;23(9):287\u201394. https:\/\/doi.org\/10.1038\/cgt.2016.28.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"1699_CR68","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1080\/00365521.2016.1190399","volume":"51","author":"Q Yu","year":"2016","unstructured":"Yu Q, Wang X, Wang L, Zheng J, Wang J, Wang B. Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells. Scand J Gastroenterol. 2016;51(10):1220\u20136. https:\/\/doi.org\/10.1080\/00365521.2016.1190399.","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"1699_CR69","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove C, Pilotte L, Th\u00e9ate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269\u201374. https:\/\/doi.org\/10.1038\/nm934.","journal-title":"Nat Med"},{"issue":"1","key":"1699_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0798-9","volume":"17","author":"M Poliakov\u00e1","year":"2018","unstructured":"Poliakov\u00e1 M, Aebersold DM, Zimmer Y, Medov\u00e1 M. The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Mol Cancer. 2018;17(1):1\u201312. https:\/\/doi.org\/10.1186\/s12943-018-0798-9.","journal-title":"Mol Cancer"},{"issue":"11","key":"1699_CR71","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1089\/omi.2020.0144","volume":"24","author":"H Taymaz-Nikerel","year":"2020","unstructured":"Taymaz-Nikerel H, Eraslan S, K\u0131rdar B. Insights into the mechanism of anticancer drug imatinib revealed through multi-omic analyses in yeast. OMICS. 2020;24(11):667\u201378. https:\/\/doi.org\/10.1089\/omi.2020.0144.","journal-title":"OMICS"},{"issue":"10","key":"1699_CR72","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/omi.2012.0012","volume":"16","author":"SC dos Santos","year":"2012","unstructured":"dos Santos SC, Mira NP, Moreira AS, S\u00e1-Correia I. Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension. OMICS. 2012;16(10):537\u201351. https:\/\/doi.org\/10.1089\/omi.2012.0012.","journal-title":"OMICS"},{"issue":"2","key":"1699_CR73","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.pharmthera.2010.04.012","volume":"127","author":"AM Smith","year":"2010","unstructured":"Smith AM, Ammar R, Nislow C, Giaever G. A survey of yeast genomic assays for drug and target discovery. Pharmacol Ther. 2010;127(2):156\u201364. https:\/\/doi.org\/10.1016\/j.pharmthera.2010.04.012.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1699_CR74","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/1567-1364.12094","volume":"14","author":"N Guaragnella","year":"2014","unstructured":"Guaragnella N, Palermo V, Galli A, Moro L, Mazzoni C, Giannattasio S. The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1\/2. FEMS Yeast Res. 2014;14(1):2\u201316. https:\/\/doi.org\/10.1111\/1567-1364.12094.","journal-title":"FEMS Yeast Res"},{"issue":"5","key":"1699_CR75","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.bbagen.2012.09.008","volume":"1830","author":"SC Lu","year":"2013","unstructured":"Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830(5):3143\u201353. https:\/\/doi.org\/10.1016\/j.bbagen.2012.09.008.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"1699_CR76","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/ncb3389","volume":"18","author":"AG Cox","year":"2016","unstructured":"Cox AG, Hwang KL, Brown KK, Evason KJ, Beltz S, Tsomides A, et al. Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol. 2016;18(8):886\u201396. https:\/\/doi.org\/10.1038\/ncb3389.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"1699_CR77","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.micres.2014.04.003","volume":"169","author":"TP West","year":"2014","unstructured":"West TP. Pyrimidine nucleotide synthesis in Pseudomonas nitroreducens and the regulatory role of pyrimidines. Microbiol Res. 2014;169(12):954\u20138. https:\/\/doi.org\/10.1016\/j.micres.2014.04.003.","journal-title":"Microbiol Res"},{"key":"1699_CR78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.nutr.012809.104810","volume":"30","author":"AS Tibbetts","year":"2010","unstructured":"Tibbetts AS, Appling DR. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr. 2010;30:57\u201381. https:\/\/doi.org\/10.1146\/annurev.nutr.012809.104810.","journal-title":"Annu Rev Nutr"},{"key":"1699_CR79","first-page":"259","volume-title":"Dynamics in the purine nucleotides of liver during various periods of hypoxia\/ischaemia and reoxygenation","author":"G Gerber","year":"1991","unstructured":"Gerber G, Siems W, Werner A, Dubiel W, Grune T, Henke W, et al. Dynamics in the purine nucleotides of liver during various periods of hypoxia\/ischaemia and reoxygenation. Boston: Springer; 1991. p. 259\u201364."},{"issue":"1","key":"1699_CR80","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/ijms21010088","volume":"21","author":"SG Miller","year":"2019","unstructured":"Miller SG, Hafen PS, Brault JJ. Increased adenine nucleotide degradation in skeletal muscle atrophy. Int J Mol Sci. 2019;21(1):88. https:\/\/doi.org\/10.3390\/ijms21010088.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1699_CR81","doi-asserted-by":"publisher","first-page":"13349","DOI":"10.18632\/aging.202962","volume":"13","author":"J Ma","year":"2021","unstructured":"Ma J, Zhong M, Xiong Y, Gao Z, Wu Z, Liu Y, et al. Emerging roles of nucleotide metabolism in cancer development: progress and prospect. Aging. 2021;13(9):13349\u201358. https:\/\/doi.org\/10.18632\/aging.202962.","journal-title":"Aging"},{"issue":"1","key":"1699_CR82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1586\/era.11.175","volume":"12","author":"K Madaan","year":"2012","unstructured":"Madaan K, Kaushik D, Verma T. Hydroxyurea: a key player in cancer chemotherapy. Expert Rev Anticancer Ther. 2012;12(1):19\u201329. https:\/\/doi.org\/10.1586\/era.11.175.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"1699_CR83","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF00686113","volume":"34","author":"T Szekeres","year":"1994","unstructured":"Szekeres T, Gharehbaghi K, Fritzer M, Woody M, Srivastava A, v\u2019ant Riet B, Jayaram HN, Elford HL. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol. 1994;34(1):63\u20136. https:\/\/doi.org\/10.1007\/BF00686113.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1699_CR84","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96(3):925\u201332.","journal-title":"Blood"},{"issue":"25","key":"1699_CR85","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1038\/sj.onc.1206620","volume":"22","author":"MO Nowicki","year":"2003","unstructured":"Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene. 2003;22(25):3952\u201363. https:\/\/doi.org\/10.1038\/sj.onc.1206620.","journal-title":"Oncogene"},{"issue":"8","key":"1699_CR86","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1182\/blood-2004-10-3864","volume":"105","author":"JJ Gu","year":"2005","unstructured":"Gu JJ, Santiago L, Mitchell BS. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood. 2005;105(8):3270\u20137. https:\/\/doi.org\/10.1182\/blood-2004-10-3864.","journal-title":"Blood"},{"issue":"1","key":"1699_CR87","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3892\/mmr.2017.7952","volume":"17","author":"L Kroschwald","year":"2017","unstructured":"Kroschwald L, Suttorp M, Tauer J, Zimmermann N, Gunther C, Bauer A. Off-target effect of imatinib and nilotinib on human vitamin D3 metabolism. Mol Med Rep. 2017;17(1):1382\u20138. https:\/\/doi.org\/10.3892\/mmr.2017.7952.","journal-title":"Mol Med Rep"},{"key":"1699_CR88","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bcp.2018.07.001","volume":"155","author":"VL Damaraju","year":"2018","unstructured":"Damaraju VL, Kuzma M, Cass CE, Putman CT, Sawyer MB. Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes. Biochem Pharmacol. 2018;155:162\u201371. https:\/\/doi.org\/10.1016\/j.bcp.2018.07.001.","journal-title":"Biochem Pharmacol"},{"key":"1699_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01106","author":"J Bouitbir","year":"2020","unstructured":"Bouitbir J, Panajatovic MV, Frechard T, Roos NJ, Kr\u00e4henb\u00fchl S. Imatinib and dasatinib provoke mitochondrial dysfunction leading to oxidative stress in C2C12 myotubes and human RD cells. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.01106.","journal-title":"Front Pharmacol"},{"key":"1699_CR90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbrc.2021.03.166","volume":"557","author":"R Fr\u00f6bom","year":"2021","unstructured":"Fr\u00f6bom R, Berglund E, Aspinwall CA, Lui W-O, Nilsson I-L, Larsson C, et al. Direct interaction of the ATP-sensitive K+ channel by the tyrosine kinase inhibitors imatinib, sunitinib and nilotinib. Biochem Biophys Res Commun. 2021;557:14\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2021.03.166.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01699-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T12:34:11Z","timestamp":1656419651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01699-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":90,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01699-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This article does not contain any studies with human research participants, so informed consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"95"}}